Daparyl M 5/1000 Tablet

Daparyl M 5/1000 Tablet contains Dapagliflozin 5 mg + Metformin Hydrochloride 1000 mg (usually extended-release). Prescription required.

Type 2 diabetes mellitus (as an adjunct to diet and exercise) to improve glycaemic control when dual therapy is appropriate or when patients are uncontrolled on metformin or an SGLT2 inhibitor alone

Dapagliflozin is an SGLT2 inhibitor that lowers blood glucose by increasing urinary glucose excretion from the kidneys. Metformin reduces hepatic glucose production and improves insulin sensitivity, decreasing intestinal glucose absorption and improving peripheral glucose uptake.

Oral tablet. Take exactly as prescribed; commonly taken once daily with food (preferably with the evening meal if extended-release) to reduce stomach upset. Swallow whole; do not crush/chew if ER. Maintain adequate hydration; monitor blood glucose as advised.

Nausea,diarrhoea,abdominal discomfort,loss of appetite,genital fungal infection,urinary tract infection,increased urination,thirst,dizziness,headache

Not for type 1 diabetes. Risk of lactic acidosis with metformin (higher risk in kidney impairment, dehydration, severe infection, heavy alcohol use, liver disease, heart failure, hypoxia); seek urgent care for fast breathing, severe weakness, abdominal pain, drowsiness. Dapagliflozin may cause genital mycotic infections, UTIs, volume depletion/low BP, and rare ketoacidosis (can occur with near-normal sugars); stop and seek care if nausea/vomiting, abdominal pain, rapid breathing. Assess renal function before and during therapy; dose/continuation depends on eGFR and product label. Temporarily withhold during acute illness, prolonged fasting, major surgery, or dehydration. Hold metformin around iodinated contrast procedures as per clinician advice. Monitor for hypoglycaemia if used with insulin/sulfonylureas.

Alcohol (increases lactic acidosis risk),insulin and sulfonylureas (increased hypoglycaemia),diuretics/antihypertensives (enhanced dehydration/hypotension),iodinated contrast media (lactic acidosis risk—temporary stop),carbonic anhydrase inhibitors e.g. topiramate/acetazolamide (metabolic acidosis risk),cimetidine (may increase metformin levels),rifampicin (may alter dapagliflozin exposure),NSAIDs/ACE inhibitors/ARBs (renal function changes—monitor)

Store below 25°C in a cool, dry place. Protect from moisture and direct light. Keep in original blister pack and out of reach of children.

Xigduo XR 5/1000 Tablet,Glempa-M 5/1000 Tablet,Dapamet XR 5/1000 Tablet,Dapaflo-M XR 5/1000 Tablet,Daplo-M XR 5/1000 Tablet